PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18097747-0	2008	The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.	argatroban	23-33	secreted phosphoprotein 1	Homo sapiens	86-97	
18097747-0	2008	The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.	argatroban	23-33	secreted phosphoprotein 1	Homo sapiens	112-123	
18097747-6	2008	In vitro assays demonstrated that Argatroban treatment (25 microg/ml) of 468-OPN cells resulted in decreased cell growth, colony-forming ability, adhesion, and migration relative to untreated controls (P < 0.05), but did not have a significant effect on 468-CON cells.	argatroban	34-44	secreted phosphoprotein 1	Homo sapiens	77-80	
18097747-7	2008	Following mammary fat pad injection, treatment with Argatroban (9 mg/kg/day) increased the in vivo tumor latency of both 468-CON and 468-OPN cells, and reduced primary tumor growth of 468-OPN cells (relative to untreated controls; P < 0.05).	argatroban	52-62	secreted phosphoprotein 1	Homo sapiens	137-140	
18097747-7	2008	Following mammary fat pad injection, treatment with Argatroban (9 mg/kg/day) increased the in vivo tumor latency of both 468-CON and 468-OPN cells, and reduced primary tumor growth of 468-OPN cells (relative to untreated controls; P < 0.05).	argatroban	52-62	secreted phosphoprotein 1	Homo sapiens	188-191	
18097747-9	2008	These novel findings indicate that inhibition of thrombin can reduce malignant and metastatic behavior of MDA-MB-468 breast cancer cells using both OPN-dependent and OPN-independent mechanisms, and suggest that thrombin inhibitors such as Argatroban may hold potential as therapeutic agents to combat breast cancer progression.	argatroban	239-249	secreted phosphoprotein 1	Homo sapiens	166-169